Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic use. Found 402 abstracts

no pagination
Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head & neck. 2002 May;24(5):437-42.
Sun W, Stevenson JP, Gallo JM, Redlinger M, Haller D, Algazy K, Giantonio B, Alila H, O'Dwyer PJ. Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. Clin Cancer Res. 2002 Oct;8(10):3100-4.
Sweeney CW. Understanding peripheral neuropathy in patients with cancer: background and patient assessment. Clinical journal of oncology nursing. 2002 May;6(3):163-6.
Torosian M, O'Shaughnessy J, Parker LM, Vogel C. Fulvestrant: clinical application of an estrogen receptor downregulator. Clinical therapeutics. 2002 Jan;24 Suppl A:A31-40.
Wang L, Yorke E, Desobry G, Chui CS. Dosimetric advantage of using 6 MV over 15 MV photons in conformal therapy of lung cancer: Monte Carlo studies in patient geometries. J Appl Clin Med Phys. 2002 Jan;3(1):51-9.
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug;20(15):3317-27.
Adams GP, Weiner LM. Radioimmunotherapy of solid tumors: from fairytale to reality. Cancer Biother Radiopharm. 2001 Feb;16(1):9-11.
Baselli EC, Greenberg RE. Maintenance therapy for superficial bladder cancer. Oncology (Huntingt). 2001 Jan;15(1):85-8; discussion 88-91.
Bast RC, Mills GB, Young RC. Translational research--traffic on the bridge. Biomed Pharmacother. 2001 Nov;55(9-10):565-71.
Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2001 Jan;11 Suppl 1:42-51.
Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol. 2001 Oct;31(10):3016-25.
Cianfrocca M, Goldstein LJ. Operable breast cancer. Current treatment options in oncology. 2001 Apr;2(2):157-67.
Clapper ML, Chang WC, Meropol NJ. Chemoprevention of colorectal cancer. Curr Opin Oncol. 2001 Jul;13(4):307-13.
Cohen RB, Dittrich KA. Anti-TNF therapy and malignancy - a critical review. Can J Gastroenterol. 2001 Jun;15(6):376-84.
Cornfeld MJ, Jadwin A, O'Grady P, Babb J, Engstrom PF. Feasibility of assessing quality in medical oncology practices. Cancer Pract. 2001 Sep;9(5):231-5.
Fleming GF, Fowler JM, Waggoner SE, Copeland LJ, Greer BE, Horowitz I, Sutton G, Schilder RJ, Fracasso PM, Ball HG, McGuire WP. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Feb 15;19(4):1021-9.
Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res. 2001 Jan;7(1):153-7.
Haas NB. Can chemotherapy alter the course of prostate cancer?. Semin Urol Oncol. 2001 Aug;19(3):212-21.
Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T, Hudes G. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology. 2001 Jul;58(1):59-64.
Held-Warmkessel J. Treatment of advanced prostate cancer. Semin Oncol Nurs. 2001 May;17(2):118-28.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic use

Human therapeutic use drug therapy pathology Female Male Antineoplastic Combined Chemotherapy Protocols Neoplasms antagonists & inhibitors US Gov't Support-PHS Breast Neoplasms Non-US Gov't Support Middle Age adverse Paclitaxel effects analogs & derivatives Animal therapy administration & dosage Aged drug effects Antineoplastic Agents adverse effects Disease-Free Survival radiotherapy Mice Adult Survival Analysis Prostatic Neoplasms Monoclonal Antibodies prevention & control Hormonal Antineoplastic Agents Cisplatin Tamoxifen pharmacology Randomized Controlled Trials Oral Administration Adenocarcinoma 80 and over Aged Estramustine metabolism Prognosis Drug Administration Schedule Cultured Tumor Cells mortality Fluorouracil Aromatase immunology Medical Oncology pharmacokinetics Case Report Doxorubicin Adjuvant Chemotherapy chemically induced etiology enzymology Treatment Outcome Combined Modality Therapy Disease Progression Feasibility Studies 4-Butyrolactone Radiation Dose-Response Relationship numerical data Lung Neoplasms Topotecan Antibody Affinity Health Care Quality Indicators Medical Informatics Computing Fatty Acid Synthetase Complex Tetrazolium Salts Antigen-Antibody Reactions Nitriles Immunoenzyme Techniques Maximum Tolerated Dose Radioimmunotherapy Antifungal Antibiotics epidemiology Middle Aged Research Urologic Surgical Procedures surgery diagnostic use Remission Induction Gastrointestinal Agents Transitional Cell Carcinoma Postmenopause Monte Carlo Method Phosphodiesterase Inhibitors Local Neoplasm Recurrence Carcinoma Granulocyte Colony-Stimulating Factor Molecular Weight Bladder Neoplasms Interleukin-2 dosage Animal Disease Models Pain Peripheral Nervous System Diseases Immunoglobulin Fragments Nude Mice IgG Receptors Radiometry Edema biosynthesis Non-Steroidal Anti-Inflammatory Agents cytology Estradiol Neoplasm Antibodies Mitoxantrone methods Cerulenin Patient Care Planning Sulindac statistics & numerical data Cell Survival Practice Guidelines Antineoplastic Antibiotics Chimeric Proteins Antineoplastic Antimetabolites Drug Design Peripheral Nerves Methotrexate US Gov't Support-Non-PHS Neoplasm Drug Resistance Thiazoles United States Liposomes Neoplasm Transplantation CD56 Antigens statistics & Androgen Antagonists Carcinoembryonic Antigen Mesothelioma Photons diagnosis Evidence-Based Medicine Carboplatin Cytokines Diet Therapy Quality of Life Paraffin Embedding Goserelin physiology Oncologic Nursing Squamous Cell Carcinoma Drug Dose-Response Relationship Neoplasm Antigens Vitamins Mesothelial Neoplasms
Last updated on Wednesday, August 05, 2020